Patents Assigned to Fondazione Centro San Raffaele Del Monte Tabor
-
Patent number: 9556438Abstract: A gene vector comprising a miRNA sequence target.Type: GrantFiled: July 15, 2014Date of Patent: January 31, 2017Assignees: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR, FONDAZIONE TELETHONInventors: Luigi Naldini, Brian Brown
-
Publication number: 20120149052Abstract: The instant invention refers to an optical method to extrapolate cell membrane conductance by indirect measurement of changes in transmembrane voltage, upon exposure of a cell sample to electric current pulses. The method is advantageously used for evaluating the activity of molecules able to alter, directly or indirectly, membrane permeability. A specific field of application is the screening of candidate compounds putatively acting on ion channel activity. In particular, it is open to the study of all ion channels with no limitations on the mechanisms of activation or to the ion species involved. The method is also advantageously used for evaluating a cell status, namely a differentiative or a pathologic status.Type: ApplicationFiled: July 16, 2010Publication date: June 14, 2012Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Fabio Grohovaz, Stefano Pitassi, Andrea Domenico Menegon
-
Publication number: 20120128643Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.Type: ApplicationFiled: April 30, 2010Publication date: May 24, 2012Applicants: FONDAZIONE TELETHON, FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
-
Publication number: 20120027802Abstract: It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed.Type: ApplicationFiled: September 22, 2011Publication date: February 2, 2012Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Maria Chiara BONINI, Attilio BONDANZA
-
Patent number: 8071380Abstract: The present invention discloses the isolation and characterization of cells isolated either from adult skeletal muscle or from adult cardiac muscle. These cells are used for the treatment of muscular disorders including muscular dystrophy and cardiopathics, respectively.Type: GrantFiled: February 15, 2007Date of Patent: December 6, 2011Assignee: Fondazione Centro San Raffaele Del Monte TaborInventors: Giulio Cossu, Beatriz Galvez Gonzales, Rossana Tonlorenzi
-
Publication number: 20110218234Abstract: A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells.Type: ApplicationFiled: November 11, 2009Publication date: September 8, 2011Applicants: Fondazione Centro San Raffaele Del Monte Tabor, Fondazione TelethonInventors: Andrea Annoni, Alessio Cantore, Luigi Naldini, Maria Grazia Roncarolo
-
Publication number: 20110117226Abstract: An enriched conglutin-? protein extract from lupin seeds having a % by weight of conglutin-? between 10 and 30%, or a conglutin-? protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplement or integrator.Type: ApplicationFiled: May 28, 2009Publication date: May 19, 2011Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Ileana Marina Terruzzi, Livio Luzi
-
Publication number: 20100323385Abstract: The present invention is directed to a method for isolating and establishing Growth Factor-Independent (GF-I) Tumor Stem Cells (TSCs) from tumor biopsies or tumor cell lines consisting in culturing cells in serum-free mitogen-free culture medium. The method discloses cell growth in a culture medium, which does neither comprise serum, nor EGF (Epidermal Growth factor) and FGF-2 (Fibroblast Growth Factor), nor both, nor EGF or FGF-2 derivatives with the same mitogenic characteristics of the parent molecules. According to a preferred embodiment, the method is directed to the isolation of Tumor stem cells (TSCs) from glioblastoma multiforme (GBM) or from other brain tumors or brain tumor cell lines. GF-Independent TSCs can be identified and expanded in vitro providing a homogeneous population of multipotent, self-renewing and highly tumorigenic Growth Factor-Independent TSCs, distinguishable from tumor stem cells derived with other methods, grown in parallel, for the above characteristics.Type: ApplicationFiled: February 15, 2008Publication date: December 23, 2010Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventor: Rossella Galli
-
Publication number: 20100297137Abstract: Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation.Type: ApplicationFiled: May 26, 2006Publication date: November 25, 2010Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Federico Caligaris-Cappio, Cristina Scielzo, Paolo Prospero Ghia, Massimo Alessio
-
Patent number: 7833789Abstract: The present invention relates to human and mouse monocyte cells expressing Tie2 and CD14 or CD16 and their use in methods for regulating angiogenesis and vascular integrity, such as methods of inducing angiogenesis, promoting vessel growth or stabilization, treating pathological disorders, inhibiting angiogenesis, and diagnosing or monitoring a pathological disorder.Type: GrantFiled: July 31, 2007Date of Patent: November 16, 2010Assignees: Fondazione Centro San Raffaele del Monte Tabor, Fondazione TelethonInventors: Luigi Naldini, Michele De Palma, Mary Anna Lucia Venneri
-
Patent number: 7795386Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.Type: GrantFiled: December 21, 2005Date of Patent: September 14, 2010Assignees: Molmed SpA, Fondazione Centro San Raffaele del Monte TaborInventors: Angelo Corti, Flavio Curnis
-
Patent number: 7737256Abstract: The invention herein disclosed relates to the anti-HIV action of uPAR-activators or activated uPAR molecules, the control of chemotaxis and cell migration by agents interfering with uPAR activation, a method for determining activated uPAR forms, the use of agents interfering with uPA/uPAR interaction for the diagnosis or therapy of diseases.Type: GrantFiled: January 22, 2002Date of Patent: June 15, 2010Assignee: Fondazione Centro San Raffaele Del Monte TaborInventors: Francesco Blasi, Nicolai Sidenius, Massimo Resnati, Anna Mondino, Guido Poli, Massimo Alfano
-
Publication number: 20100041145Abstract: The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.Type: ApplicationFiled: March 30, 2007Publication date: February 18, 2010Applicants: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR, FONDAZIONE TELETHONInventors: Silvia Adriana Gregori, Maria Grazia Roncarolo, Rosa Bacchetta
-
Publication number: 20100041737Abstract: A gene vector comprising a miRNA sequence target.Type: ApplicationFiled: May 26, 2006Publication date: February 18, 2010Applicants: Fondazione Centro San Raffaele Del Monte Tabor, Fondazione TelethonInventors: Luigi Naldini, Brian Brown
-
Publication number: 20090317909Abstract: The present invention discloses the isolation and characterization of cells isolated either from adult skeletal muscle or from adult cardiac muscle. These cells are used for the treatment of muscular disorders including muscular dystrophy and cardiopathics, respectively.Type: ApplicationFiled: February 15, 2007Publication date: December 24, 2009Applicant: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABORInventors: Giulio Cossu, Beatriz Galvez Gonzales, Rossana Tonlorenzi
-
Patent number: 7622556Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.Type: GrantFiled: October 25, 2006Date of Patent: November 24, 2009Assignee: Fondazione Centro San Raffaele Del Monte TaborInventor: Angelo Corti
-
Patent number: 7622105Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.Type: GrantFiled: January 25, 2006Date of Patent: November 24, 2009Assignee: Fondazione Centro San Raffaele Del Monte TaborInventor: Angelo Corti
-
Publication number: 20090092663Abstract: The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems.Type: ApplicationFiled: August 29, 2008Publication date: April 9, 2009Applicants: G. Gaslini Children's Hospital, Fondazione Centro San Raffaele Del Monte Tabor, The Governors of the University of AlbertaInventors: Mirco Ponzoni, Angelo Corti, Theresa M. Allen
-
Patent number: 7476721Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.Type: GrantFiled: June 27, 2005Date of Patent: January 13, 2009Assignee: Fondazione Centro San Raffaele Del Monte TaborInventor: Angelo Corti
-
Patent number: 7309694Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.Type: GrantFiled: November 5, 2002Date of Patent: December 18, 2007Assignee: Fondazione Centro San Raffaele Del Monte TaborInventor: Angelo Corti